Buse, M.D., from the University of North Carolina School of Medicine in Chapel Hill, and colleagues randomly assigned 2,713 adults with inadequately controlled type 2 diabetes receiving metformin with or without SGLT2i with overweight or obesity to receive cagrilintide-semaglutide, semaglutide, cagrilintide, or placebo for 68 weeks
Both peptides remain on the WADA Prohibited List under growth factors and growth factor modulators, which affects athlete eligibility separately from criminal law [unverified]
After peaking at a record 39.9% in 2022, the adult obesity rate has gradually fallen to 36.4% in 2026
Major depression and its recurrences: life course matters
100% vegan product
Our cosmetic-grade L glutathione powder may help lighten your skin tone and fade the appearance of blemishes